Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OPGNNASDAQ:SECONASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOPGNOpGen$4.70-1.3%$4.42$0.53▼$5.25$47.32M-1.7110,156 shs2,035 shsSECOSecoo$0.41$0.26▼$2.73N/A-0.04286,414 shs425,400 shsTPSTTempest Therapeutics$5.98-2.5%$7.37$5.35▼$47.45$22M-1.78159,297 shs11,908 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOPGNOpGen+1.28%-2.46%-4.61%+433.33%+34.46%SECOSecoo0.00%0.00%0.00%0.00%0.00%TPSTTempest Therapeutics-2.70%-2.54%-16.49%-41.74%-86.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/ASECOSecooN/AN/AN/AN/AN/AN/AN/AN/ATPSTTempest Therapeutics1.7537 of 5 stars3.33.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOPGNOpGen 0.00N/AN/AN/ASECOSecoo 0.00N/AN/AN/ATPSTTempest Therapeutics 2.50Moderate Buy$30.00402.09% UpsideCurrent Analyst Ratings BreakdownLatest OPGN, TPST, and SECO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$16.00 ➝ $16.004/10/2025TPSTTempest TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Perform$7.00 ➝ $9.003/28/2025TPSTTempest TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$169.00 ➝ $91.003/28/2025TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$611.00 ➝ $208.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOPGNOpGen$2.67M17.70N/AN/A($11.55) per share-0.41SECOSecoo$491.42MN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/A$1.39 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%6/2/2025 (Estimated)SECOSecoo-$88.80MN/A0.00N/AN/AN/AN/AN/AN/ATPSTTempest Therapeutics-$29.49M-$17.98N/AN/AN/AN/A-187.44%-82.61%8/14/2025 (Estimated)Latest OPGN, TPST, and SECO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025TPSTTempest Therapeutics-$3.71-$3.16+$0.55-$3.16N/AN/A3/27/2025Q4 2024TPSTTempest Therapeutics-$3.12-$4.03-$0.91-$0.31N/A$0.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOPGNOpGenN/AN/AN/AN/AN/ASECOSecooN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOPGNOpGenN/A5.455.45SECOSecooN/AN/AN/ATPSTTempest TherapeuticsN/A1.691.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOPGNOpGen2.68%SECOSecooN/ATPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipOPGNOpGen43.80%SECOSecoo18.80%TPSTTempest Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOPGNOpGen10010.07 million4.70 millionNot OptionableSECOSecoo509N/AN/ANot OptionableTPSTTempest Therapeutics203.68 million41.59 millionOptionableOPGN, TPST, and SECO HeadlinesRecent News About These CompaniesQ2 EPS Estimate for Tempest Therapeutics Raised by AnalystMay 20, 2025 | americanbankingnews.comTempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deTempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finance.yahoo.comTempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comTempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual MeetingApril 28, 2025 | globenewswire.comDual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous PolyposisApril 25, 2025 | empr.comCash-strapped Bay Area biotech company lays off all but 5 employeesApril 24, 2025 | msn.comTempest Therapeutics: FDA Grants Orphan Drug Designation To TPST-1495April 23, 2025 | nasdaq.comTempest Therapeutics Receives FDA Orphan Drug Designation for TPST-1495 to Treat Familial Adenomatous PolyposisApril 23, 2025 | nasdaq.comTempest TherapeuticsApril 22, 2025 | thepharmaletter.comTempest Therapeutics stock rises on FDA Orphan Drug DesignationApril 21, 2025 | in.investing.comTempest lays off 80% of workforce to ride out cash crunchApril 21, 2025 | fiercebiotech.comTempest Therapeutics announces FDA granted ODD to TPST-1495April 21, 2025 | markets.businessinsider.comTempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAPApril 21, 2025 | globenewswire.comScotiabank Downgrades Tempest Therapeutics (TPST)April 11, 2025 | msn.comTempest Therapeutics downgraded to Sector Perform from Outperform at ScotiabankApril 10, 2025 | markets.businessinsider.comTempest Therapeutics downgraded to Neutral from Buy at H.C. WainwrightApril 10, 2025 | markets.businessinsider.comTempest hits funding block for Phase III liver cancer drug-in-waitingApril 10, 2025 | finance.yahoo.comTempest, weathering stormy capital markets, hunts for partners for liver cancer drugApril 10, 2025 | fiercebiotech.comTempest to explore alternatives to advance promising pipelineApril 10, 2025 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPGN, TPST, and SECO Company DescriptionsOpGen NASDAQ:OPGN$4.70 -0.06 (-1.26%) As of 12:50 PM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Secoo NASDAQ:SECOSecoo Holding Limited, through its subsidiaries, operates an integrated online and offline shopping platform in the People's Republic of China, Hong Kong, and internationally. It provides upscale brand products and services, including handbags, watches, clothing, footwear, jewelry and accessories, cosmetics and skincare, home accessories, sportswear, home goods, fine food and beverage products, arts, 3C electronic devices, and Chinese original products, as well as lifestyle services through its website, mobile applications, and offline experience centers. The company also offers its website as a marketplace to third party merchants to facilitate their sales of upscale products and services. Secoo Holding Limited was incorporated in 2011 and is headquartered in Beijing, China.Tempest Therapeutics NASDAQ:TPST$5.98 -0.16 (-2.53%) As of 01:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
